SBIR/STTR Research Award

Ultrasensitive Point-of-Care Diagnostics of Viral Biomarkers and Infectious Diseases

Award identifier bfd4d09295d783c9f93c83f3e945838c781981910b25ce0c205cfbf697b425ceAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$300,000

Program and phase

STTR · Phase I

Award year

2016

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ARISAN THERAPEUTICS INC
Proposal award date
2016-08-01
Contract end date
2018-07-31
UEI
PYRKTQPNVJZ8
Solicitation number
PA15-270
Topic code
NIAID

Research abstract

Project Summary Linking infectious agent diagnostics to clinical decision making at the point of care requires a fast highly sensitive and simple to use method that takes into account the infrastructure and workflow in clinical settings of both developing and developed regions In addition being able to distinguish among multiple potential infectious pathogens in a single test is of great importance as many pathogens cause similar symptoms The goal of this phase I proposal is to develop and validate a highly sensitive biosensor diagnostic platform allowing naked eye detection of viral antigens at pM concentration in human serum Our initial focus will be on antigens from hemorrhagic fever viruses including Ebola and Dengue that are classified as Category A NIAID priority pathogens The proposed diagnostic platform integrates three key features i high efficiency capture and isolation of biomarkers ii surface enrichment on sensing surfaces and iii label free naked eye detection at low concentrations The sensitivity of the nanohole sensor is based on two important scientific discoveries i Extraordinary Light Transmission EOT effect and ii highly dispersive plasmonic Fano resonances that eliminates the need for powered operated light sources or optical detectors Recombinant viral proteins spiked in commercially available human serum will be used to evaluate the sensitivity specificity and reliability of this diagnostic platform At the end of this phase I grant a working nanophotonic prototype will provide the basis for advancing this novel viral diagnostic platform for phase II development Narrative Sensitive fast reliable user friendly and equipment free point of care diagnostic s is needed to differentially diagnose among various viral and non viral infectious diseases for better patient management and the initiation of proper treatment regime in a timely manner

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

16 SBIR/STTR records share this UEI (2011–2024). Reported award amounts total $15,835,806. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.